Taking people in Hollandia4. fázis
PROTECx - Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer
Key facts
- Where
- Amsterdam, Eindhoven, Enschede, Groningen, Leiden, Maastricht, Nijmegen, Rotterdam, Utrecht és Zwolle, HollandiaSee the 11 sites
- Phase
- 4. fázis
Where in Hollandia
- Amsterdam UMC StichtingAmsterdam, HollandiaTaking people
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAmsterdam, HollandiaTaking people
- Catharina Ziekenhuis StichtingEindhoven, HollandiaTaking people
- Medisch Spectrum TwenteEnschede, HollandiaTaking people
- Universitair Medisch Centrum GroningenGroningen, HollandiaTaking people
- Leids Universitair Medisch Centrum (LUMC)Leiden, HollandiaTaking people
- Academisch Ziekenhuis MaastrichtMaastricht, HollandiaTaking people
- Radboud universitair medisch centrum StichtingNijmegen, HollandiaTaking people
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, HollandiaTaking people
- Universitair Medisch Centrum UtrechtUtrecht, HollandiaTaking people
- Isala Klinieken StichtingZwolle, HollandiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universitair Medisch Centrum Groningen
- Trial code
- EU 2025-522883-34-00
- Record updated
- 2026. május 11.
- Original description
• To evaluate the PFS at 12 months and compare to the historical PFS of the KEYNOTE-826 trial.Read full original descriptionShow less
• To evaluate the PFS at 12 months and compare to the historical PFS of the KEYNOTE-826 trial.
Exclusion: Malignant other disease other than cervical carcinoma that required active treatment in the past 2 years: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, transitional cell carcinoma of urothelial cancer, or any carcinoma in situ that have undergone potentially curative therapy are not excluded; Any condition, in opinion of the investigator, that may hamper compliance to the study procedures; Insufficient proficiency in written and spoken Dutch to understand the study information, complete Dutch language questionnaires, or provide informed consent will be excluded.